Ocugen (2H51) Stock Overview
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
2H51 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Ocugen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.94 |
| 52 Week High | US$2.35 |
| 52 Week Low | US$0.52 |
| Beta | 2.9 |
| 1 Month Change | 57.18% |
| 3 Month Change | 53.02% |
| 1 Year Change | 264.35% |
| 3 Year Change | 137.69% |
| 5 Year Change | -67.51% |
| Change since IPO | 4.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2H51 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.2% | 0.5% | -2.7% |
| 1Y | 264.3% | -8.0% | -3.9% |
Return vs Industry: 2H51 exceeded the German Biotechs industry which returned -8% over the past year.
Return vs Market: 2H51 exceeded the German Market which returned -3.9% over the past year.
Price Volatility
| 2H51 volatility | |
|---|---|
| 2H51 Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2H51's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2H51's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 116 | Shankar Musunuri | www.ocugen.com |
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
Ocugen, Inc. Fundamentals Summary
| 2H51 fundamental statistics | |
|---|---|
| Market cap | €634.31m |
| Earnings (TTM) | -€58.59m |
| Revenue (TTM) | €3.81m |
Is 2H51 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2H51 income statement (TTM) | |
|---|---|
| Revenue | US$4.41m |
| Cost of Revenue | US$39.75m |
| Gross Profit | -US$35.34m |
| Other Expenses | US$32.51m |
| Earnings | -US$67.85m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | -800.75% |
| Net Profit Margin | -1,537.41% |
| Debt/Equity Ratio | -236.7% |
How did 2H51 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/20 15:19 |
| End of Day Share Price | 2026/03/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocugen, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |